Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies

FEBS Journal

Volumn 283, Issue 1, 2016, Pages 25-38

  Maes, Hannelore ^a   Olmeda, David ^b   Soengas, María S ^b   Agostinis, Patrizia ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Structural Biology and Biocomputing Programme   (Spain)

Author keywords

angiogenesis; anticancer therapy; autophagy; cancer; endocytosis; pro angiogenic signaling; vesicular trafficking

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ADAM PROTEIN; AFLIBERCEPT; ANGIOPOIETIN 1; APOPTOSIS SIGNAL REGULATING KINASE 1; AUTOPHAGY PROTEIN 5; BEVACIZUMAB; EPHRIN B2; EPHRIN RECEPTOR; EPSIN; EVEROLIMUS; HIGH MOBILITY GROUP B1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERLEUKIN 8; JAGGED1; NEUROPILIN 1; NOTCH1 RECEPTOR; NOTCH4 RECEPTOR; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VON WILLEBRAND FACTOR; ANGIOGENESIS INHIBITOR;

ANTIANGIOGENIC THERAPY; AUTOPHAGY; BINDING AFFINITY; CANCER GROWTH; CARCINOGENESIS; CELL FUNCTION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; ENDOCYTOSIS; ENDOTHELIUM CELL; EXOSOME; HUMAN; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR VASCULARIZATION; ANIMAL; DRUG EFFECTS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOTHELIAL CELLS; HUMANS; LYMPHANGIOGENESIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN TRANSPORT;

EID: 84957729045     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13545     Document Type: Review

References (80)

1. Hanahan D, &, Coussens LM, (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322.
2. Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, Lv ZQ, Gao CY, Wang BL, Zhang YM, et al,. (2014) Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 1845, 182-201.
3. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, &, DeClerck YA, (2012) Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 72, 2473-2480.
4. Carmeliet P, &, Jain RK, (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discovery 10, 417-427.
5. De Bock K, Cauwenberghs S, &, Carmeliet P, (2011) Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications Curr Opin Gen Develop 21, 73-79.
6. Claesson-Welsh L, &, Welsh M, (2013) VEGFA and tumour angiogenesis. J Intern Med 273, 114-127.
7. Nilsson I, Bahram F, Li X, Gualandi L, Koch S, Jarvius M, Soderberg O, Anisimov A, Kholova I, Pytowski B, et al,. (2010) VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J 29, 1377-1388.
8. Zarkada G, Heinolainen K, Makinen T, Kubota Y, &, Alitalo K, (2015) VEGFR3 does not sustain retinal angiogenesis without VEGFR2. Proc Natl Acad Sci USA 112, 761-766.
9. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, &, Bohlen P, (1998) Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17, 155-161.
10. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, et al,. (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454, 656-660.
11. Herzog B, Pellet-Many C, Britton G, Hartzoulakis B, &, Zachary IC, (2011) VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Mol Biol Cell 22, 2766-2776.
12. Aspalter IM, Gordon E, Dubrac A, Ragab A, Narloch J, Vizan P, Geudens I, Collins RT, Franco CA, Abrahams CL, et al,. (2015) Alk1 and Alk5 inhibition by Nrp1 controls vascular sprouting downstream of Notch. Nat Commun 6, 7264.
13. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, et al,. (2009) DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168-177.
14. Ziyad S, &, Iruela-Arispe ML, (2011) Molecular mechanisms of tumor angiogenesis. Gen Cancer 2, 1085-1096.
15. Welti J, Loges S, Dimmeler S, &, Carmeliet P, (2013) Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Investig 123, 3190-3200.
16. Zheng W, Aspelund A, &, Alitalo K, (2014) Lymphangiogenic factors, mechanisms, and applications. J Clin Investig 124, 878-887.
17. Coso S, Bovay E, &, Petrova TV, (2014) Pressing the right buttons: signaling in lymphangiogenesis. Blood 123, 2614-2624.
18. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, &, Achen MG, (2014) Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 14, 159-172.
19. White RR, Stanley WE, Johnson JL, Tyler DS, &, Seigler HF, (2002) Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg 235, 879-887.
20. Das S, &, Skobe M, (2008) Lymphatic vessel activation in cancer. Ann N Y Acad Sci 1131, 235-241.
21. Zheng W, Tammela T, Yamamoto M, Anisimov A, Holopainen T, Kaijalainen S, Karpanen T, Lehti K, Yla-Herttuala S, &, Alitalo K, (2011) Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. Blood 118, 1154-1162.
22. Sorkin A, &, von Zastrow M, (2009) Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol 10, 609-622.
23. Tiwari A, Jung J-J, Inamdar SM, &, Choudhury A, (2012) Membrane trafficking and endothelial-cell dynamics during angiogenesis. In Hematology-Science and Practice (, Lawrie CH, ed). InTech, Rijeka, Croatia.
24. Nakayama M, Nakayama A, van Lessen M, Yamamoto H, Hoffmann S, Drexler HC, Itoh N, Hirose T, Breier G, Vestweber D, et al,. (2013) Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat Cell Biol 15, 249-260.
25. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, &, Acker-Palmer A, (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465, 487-491.
26. Ferrara N, (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2, 795-803.
27. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Luthi U, et al,. (2010) Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483-486.
28. Abengozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, Olmeda D, Marenchino M, Canamero M, Ortega S, Megias D, et al,. (2012) Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 119, 4565-4576.
29. Sen A, Madhivanan K, Mukherjee D, &, Aguilar RC, (2012) The epsin protein family: coordinators of endocytosis and signaling. Biomol Concepts 3, 117-126.
30. Pasula S, Cai X, Dong Y, Messa M, McManus J, Chang B, Liu X, Zhu H, Mansat RS, Yoon SJ, et al,. (2012) Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling. J Clin Investig 122, 4424-4438.
31. Zhou HJ, Chen X, Huang Q, Liu R, Zhang H, Wang Y, Jin Y, Liang X, Lu L, Xu Z, et al,. (2014) AIP1 mediates vascular endothelial cell growth factor receptor-3-dependent angiogenic and lymphangiogenic responses. Arterioscler Thromb Vasc Biol 34, 603-615.
32. Zhang H, He Y, Dai S, Xu Z, Luo Y, Wan T, Luo D, Jones D, Tang S, Chen H, et al,. (2008) AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory angiogenesis in mice. J Clin Investig 118, 3904-3916.
33. Koch S, van Meeteren LA, Morin E, Testini C, Westrom S, Bjorkelund H, Le Jan S, Adler J, Berger P, &, Claesson-Welsh L, (2014) NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation. Dev Cell 28, 633-646.
34. Deng Y, Zhang X, &, Simons M, (2015) Molecular controls of lymphatic VEGFR3 signaling. Arterioscler Thromb Vasc Biol 35, 421-429.
35. De Strooper B, &, Annaert W, (2010) Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu Rev Cell Dev Biol 26, 235-260.
36. Sannerud R, &, Annaert W, (2009) Trafficking, a key player in regulated intramembrane proteolysis. Semin Cell Dev Biol 20, 183-190.
37. Fortini ME, &, Bilder D, (2009) Endocytic regulation of Notch signaling. Curr Opin Genet Dev 19, 323-328.
38. Le Bras S, Loyer N, &, Le Borgne R, (2011) The multiple facets of ubiquitination in the regulation of notch signaling pathway. Traffic 12, 149-161.
39. Zheng L, Saunders CA, Sorensen EB, Waxmonsky NC, &, Conner SD, (2013) Notch signaling from the endosome requires a conserved dileucine motif. Mol Biol Cell 24, 297-307.
40. Yamamoto S, Charng WL, &, Bellen HJ, (2010) Endocytosis and intracellular trafficking of Notch and its ligands. Curr Top Dev Biol 92, 165-200.
41. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, et al,. (2015) Autophagy in malignant transformation and cancer progression. EMBO J 34, 856-880.
42. Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, Cranston DW, Li JL, &, Harris AL, (2006) Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 12, 4836-4844.
43. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, et al,. (2007) Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 67, 11244-11253.
44. Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, et al,. (2014) Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 26, 190-206.
45. Feng Y, Yao Z, &, Klionsky DJ, (2015) How to control self-digestion: transcriptional, post-transcriptional, and post-translational regulation of autophagy. Trends Cell Biol 25, 354-363.
46. Maes H, Rubio N, Garg AD, &, Agostinis P, (2013) Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med 19, 428-446.
47. Torisu T, Torisu K, Lee IH, Liu J, Malide D, Combs CA, Wu XS, Rovira II, Fergusson MM, Weigert R, et al,. (2013) Autophagy regulates endothelial cell processing, maturation and secretion of von Willebrand factor. Nat Med 19, 1281-1287.
48. Lee SJ, Kim HP, Jin Y, Choi AM, &, Ryter SW, (2011) Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis. Autophagy 7, 829-839.
49. Kim KW, Paul P, Qiao J, Lee S, &, Chung DH, (2013) Enhanced autophagy blocks angiogenesis via degradation of gastrin-releasing peptide in neuroblastoma cells. Autophagy 9, 1579-1590.
50. Sachdev U, Cui X, Hong G, Namkoong S, Karlsson JM, Baty CJ, &, Tzeng E, (2012) High mobility group box 1 promotes endothelial cell angiogenic behavior in vitro and improves muscle perfusion in vivo in response to ischemic injury. J Vasc Surg 55, 180-191.
51. Yang S, Xu L, Yang T, &, Wang F, (2014) High-mobility group box-1 and its role in angiogenesis. J Leukoc Biol 95, 563-574.
52. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, &, Griffioen AW, (2013) Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 32, 363-374.
53. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, &, Suffredini AF, (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101, 2652-2660.
54. Rivera LB, &, Bergers G, (2015) Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol 36, 240-249.
55. Puri C, Renna M, Bento CF, Moreau K, &, Rubinsztein DC, (2013) Diverse autophagosome membrane sources coalesce in recycling endosomes. Cell 154, 1285-1299.
56. Longatti A, &, Tooze SA, (2012) Recycling endosomes contribute to autophagosome formation. Autophagy 8, 1682-1683.
57. Barth JM, &, Kohler K, (2014) How to take autophagy and endocytosis up a notch. BioMed Res Int 2014, 960803.
58. Merrifield CJ, &, Kaksonen M, (2014) Endocytic accessory factors and regulation of clathrin-mediated endocytosis. Cold Spring Harbor Pers Biol 6, a016733.
59. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardi C, Thakur ML, Barker CA, Camphausen K, et al,. (2006) Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 98, 1634-1646.
60. Poluzzi C, Casulli J, Goyal A, Mercer TJ, Neill T, &, Iozzo RV, (2014) Endorepellin evokes autophagy in endothelial cells. J Biol Chem 289, 16114-16128.
61. Nguyen TM, Subramanian IV, Xiao X, Ghosh G, Nguyen P, Kelekar A, &, Ramakrishnan S, (2009) Endostatin induces autophagy in endothelial cells by modulating Beclin 1 and beta-catenin levels. J Cell Mol Med 13, 3687-3698.
62. Stapor P, Wang X, Goveia J, Moens S, &, Carmeliet P, (2014) Angiogenesis revisited-role and therapeutic potential of targeting endothelial metabolism. J Cell Sci 127, 4331-4341.
63. De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quaegebeur A, Ghesquiere B, Cauwenberghs S, Eelen G, et al,. (2013) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154, 651-663.
64. Rabinowitz JD, &, White E, (2010) Autophagy and metabolism. Science 330, 1344-1348.
65. Kluge MA, Fetterman JL, &, Vita JA, (2013) Mitochondria and endothelial function. Circ Res 112, 1171-1188.
66. Myers AL, Orr WS, Denbo JW, Ng CY, Zhou J, Spence Y, Wu J, &, Davidoff AM, (2012) Rapamycin-induced tumor vasculature remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg 47, 183-189.
67. Chen X, Liang H, Zhang J, Zen K, &, Zhang CY, (2012) Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 22, 125-132.
68. Hannafon BN, &, Ding WQ, (2013) Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci 14, 14240-14269.
69. Sheldon H, Heikamp E, Turley H, Dragovic R, Thomas P, Oon CE, Leek R, Edelmann M, Kessler B, Sainson RC, et al,. (2010) New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood 116, 2385-2394.
70. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, &, Dolo V, (2002) Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 160, 673-680.
71. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, Mercatanti A, Hammond S, &, Rainaldi G, (2006) MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108, 3068-3071.
72. Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, Iruela-Arispe ML, Merkenschlager M, &, Sessa WC, (2008) Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci USA 105, 14082-14087.
73. Bovy N, Blomme B, Freres P, Dederen S, Nivelles O, Lion M, Carnet O, Martial JA, Noel A, Thiry M, et al,. (2015) Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget 6, 10253-10266.
74. Potente M, Gerhardt H, &, Carmeliet P, (2011) Basic and therapeutic aspects of angiogenesis. Cell 146, 873-887.
75. Ebos JM, &, Kerbel RS, (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8, 210-221.
76. Huang Y, Goel S, Duda DG, Fukumura D, &, Jain RK, (2013) Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73, 2943-2948.
77. Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, Willett CG, Jain RK, &, Padera TP, (2015) Investigation of the lack of angiogenesis in the formation of lymph node metastases. J Natl Cancer Inst 107.
78. Rojas-Puentes LL, Gonzalez-Pinedo M, Crismatt A, Ortega-Gomez A, Gamboa-Vignolle C, Nunez-Gomez R, Dorantes-Gallareta Y, Arce-Salinas C, &, Arrieta O, (2013) Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases. Radiat Oncol 8, 209.
79. Boyd AW, Bartlett PF, &, Lackmann M, (2014) Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discovery 13, 39-62.
80. Soker S, Miao HQ, Nomi M, Takashima S, &, Klagsbrun M, (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 85, 357-368.